The protective effect of VSL#3 on intestinal permeability in a rat model of alcoholic intestinal injury

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Chang, Bing ^a   Sang, Lixuan ^a   wang, Ying ^a   Tong, Jing ^a   Zhang, Dai ^a   Wang, Bingyuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Glutamine; Intestinal barrier; Tight junctions; TNF ; VSL 3

Indexed keywords

ENDOTOXIN; GLUTAMINE; MESSENGER RNA; STARCH; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VSL3;

ALCOHOL LIVER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH PROTECTION; TACHYPLEUS AMEBOCTYE LYSATE ASSAY; TIGHT JUNCTION GENE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BIFIDOBACTERIUM; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DISEASE MODELS, ANIMAL; ENDOTOXINS; ETHANOL; GLUTAMINE; INTESTINAL MUCOSA; INTESTINES; LACTOBACILLUS; LIVER DISEASES, ALCOHOLIC; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; OCCLUDIN; PERMEABILITY; PROBIOTICS; RATS; STREPTOCOCCUS THERMOPHILUS; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84885556267     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-151     Document Type: Article

References (40)

1. Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001, 7(9):408-413. 10.1016/S1471-4914(01)02096-2, 11530336.
2. Rouault TA. Hepatic iron overload in alcoholic liver disease: why does it occur and what is its role in pathogenesis?. Alcohol 2003, 30(2):103-106. 10.1016/S0741-8329(03)00102-2, 12957293.
3. Keshavarzian A, Holmes EW, Patel M, et al. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol 1999, 94(1):200-207. 10.1111/j.1572-0241.1999.00797.x, 9934756.
4. Ma TY, Iwamoto GK, Hoa NT, et al. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-κB activation. Am J Physiol Gastrointest Liver Physiol 2004, 286(3):G367-G376. 10.1152/ajpgi.00173.2003, 14766535.
5. Bengmark S. Ecological control of the gastroinstinal tract: the role of probiotic flore. Gut 1998, 42(1):2-7. 10.1136/gut.42.1.2, 1726957, 9505873.
6. Simon GL, Gorbach SL. Intestinal flora in health and disease. Gastroenterology 1984, 86(1):174-193.
7. Guarner C, Runyon BA, Young S, et al. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997, 26(6):1372-1378. 10.1016/S0168-8278(97)80474-6, 9210626.
8. MacFie J, O'Boyle C, Mitchell C, et al. Gut origin of sepsis: a prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut 1999, 45(2):223-228. 10.1136/gut.45.2.223, 1727620, 10403734.
9. Othman M, Agfiero R, Lin HC. Alterations in intestinal microbial flora and human disease. Curr Opin Gastroenterol 2008, 24(1):11-16. 10.1097/MOG.0b013e3282f2b0d7, 18043226.
10. Shimizu K, Ogura H, Goto M, et al. Altered gut flora and environment in patients with severe SIRS. J Trauma 2006, 60(1):126-133. 10.1097/01.ta.0000197374.99755.fe, 16456446.
11. Li LJ, Wu ZW, Xiao DS, et al. Changes of gut flora and endotoxin in rats with D-galactosamine induced acute liver failure. World J Gastroenterol 2004, 10(14):2087-2090.
12. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989, 66(5):365-378. 10.1111/j.1365-2672.1989.tb05105.x, 2666378.
13. Abubucker S, Segata N, Goll J, et al. Metabolic reconstruction for metagen -omic data and its application to the human microbiome. PLoS Comput Biol 2012, 8(6):e1002358. 10.1371/journal.pcbi.1002358, 3374609, 22719234.
14. Brown CT, Davis-Richardson AG, Giongo A, et al. Gut microbiome meta genomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 2011, 6(10):e25792. 10.1371/journal.pone.0025792, 3197175, 22043294.
15. Lakhdari O, Cultrone A, Tap J, et al. Functional metagenomics: a high through- put screening method to decipher microbiota-driven NF-κB modulation in the human gut. PLoS One 2010, 5(9):e13092. 10.1371/journal.pone.0013092, 2948039, 20927194.
16. Murphy EF, Cotter PD, Healy S, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010, 59(12):1635-1642. 10.1136/gut.2010.215665, 20926643.
17. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464(7285):59-65. 10.1038/nature08821, 3779803, 20203603.
18. Claesson MJ, Cusack S, O'Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011, 108(Suppl 1):4586-4591. 3063589, 20571116.
19. Jalanka-Tuovinen J, Salonen A, Nikkila J, et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One 2011, 6(7):e23035. 10.1371/journal.pone.0023035, 3145776, 21829582.
20. Nam YD, Jung MJ, Roh SW, et al. Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. PLoS One 2011, 6(7):e22109. 10.1371/journal.pone.0022109, 3146482, 21829445.
21. Reeves AE, Theriot CM, Bergin IL, et al. The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. Gut Microbes 2011, 2(3):145-158. 10.4161/gmic.2.3.16333, 3225775, 21804357.
22. Sjogren YM, Jenmalm MC, Bottcher MF, et al. Altered early infant gut micro- biota in children developing allergy up to 5 years of age. Clin Exp Allergy 2009, 39(4):518-526. 10.1111/j.1365-2222.2008.03156.x, 19220322.
23. Deitch EA. Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings?. Surgery 2002, 131(3):241-244. 10.1067/msy.2002.116408, 11894026.
24. Rajilić-Stojanović M, Smidt H, de Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol 2007, 9(9):2125-2136. 10.1111/j.1462-2920.2007.01369.x, 17686012.
25. Ko TC, Beauchamp RD, Townsend CM, et al. Glutamine is essential for epidermal growth factor-stimulated intestinal cell proliferation. Surgery 1993, 114(2):147-153.
26. Scheppach W, Loges C, Bartram P, et al. Effect of free glutamine and alanyl-glutamine dipeptide on mucosal proliferation of the human ileum and colon. Gastroenterology 1994, 107(2):429-434.
27. Buchman AL, Moukarzel AA, Bhuta S, et al. Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN J Parenter Enteral Nutr 1995, 19(6):453-460. 10.1177/0148607195019006453, 8748359.
28. Van der Hulst RR, van Kreel BK, von Meyenfeldt MF, et al. Glutamine and the preservation of gut integrity. Lancet 1993, 341(8857):1363-1365. 10.1016/0140-6736(93)90939-E, 8098788.
29. Musch MW, Ciancio MJ, Sarge K, et al. Induction of heat shock protein 70 protects intestinal epithelial IEC-18 cells from oxidant and thermal injury. Am J Physiol 1996, 270(2 pt 1):C429-C436.
30. Wischmeyer PE, Musch MW, Madonna MB, et al. Glutamine protects intestinal epithelial cells: role of inducible HSP70. Am J Physiol 1997, 272(2 pt 1):G879-G884.
31. Ameho CK, Adjei AA, Harrison EK, et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 1997, 41(4):487-93. 10.1136/gut.41.4.487, 1891521, 9391247.
32. Vicario M, Amat C, Rivero M, Moreto M, et al. Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr 2007, 137(8):1931-1937.
33. Ziegler TR, Evans ME, Fernandez-Estivariz C, et al. Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function. Annu Rev Nutr 2003, 23:229-61. 10.1146/annurev.nutr.23.011702.073036, 12626687.
34. Lecleire S, Hassan A, Marion-Letellier R, et al. Combined glutamine and argin- ine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappa B and p38 mitogen-activated protein kinase pathways. J Nutr 2008, 138(12):2481-2486. 10.3945/jn.108.099127, 19022976.
35. Coeffier M, Marion R, Ducrotte P, et al. Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr 2003, 22(4):407-413. 10.1016/S0261-5614(03)00040-2, 12880609.
36. Huang Y, Li N, Liboni K, et al. Glutamine decreases lipopolysaccharide-induced IL-8 production in Caco-2 cells through a non-NF-kappaB p50 mechanism. Cytokine 2003, 22(2-3):77-83.
37. Liboni KC, Li N, Scumpia PO, et al. Glutamine modulates LPS-induced IL-8 production through IkκB/NF-κB in human fetal and adult intestinal epithelium. J Nutr 2005, 135(2):245-251.
38. Hubert-Buron A, Leblond J, Jacquot A, et al. Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IκBα ubiquitination. J Nutr 2006, 136(6):1461-1465.
39. Fillmann H, Kretzmann NA, San-Miguel B, et al. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology 2007, 236(3):217-226. 10.1016/j.tox.2007.04.012, 17543437.
40. Brasse-Lagnel C, Lavoinne A, Loeber D, et al. Glutamine and interleukin-1beta interact at the level of Sp1 and nuclear factor-kappaB to regulate argininosuccinate synthetase gene expression. FEBS J 2007, 274(20):5250-5262. 10.1111/j.1742-4658.2007.06047.x, 17892496.